Colli-Pee.
First-void urine, same volume every time.

Colli-Pee captures a fixed, standardised volume of first-void urine, the first 20 mL of the stream where urogenital cells and analytes concentrate, without a random midstream catch: collectors of 4, 10, 20 or 40 mL, prefilled where the assay needs it with a conservation medium that holds DNA for a week at room temperature. CE-marked, CE-IVD in its stabilised configurations. Curated and supplied on the Humans Nexus platform; DNA Genotek is the manufacturer.

Talk to salesHow it works →
Colli-Pee first-void urine collection device by DNA Genotek, on the Humans Nexus platform
The device

The first-catch fraction,
captured cleanly.

Colli-Pee is an all-in-one first-void urine collector: a diverter directs the very first part of the urine stream into a tube that fills to a defined volume and stops, so every sample is the same standardised first-catch fraction rather than an uncontrolled random catch. The tube can be neat or prefilled with a DNA/analyte-conservation medium that stabilises the sample for ambient transport, and is available across a range of collection volumes. Humans Nexus curates and supplies the device on its platform; DNA Genotek is the legal manufacturer; the device was invented by Novosanis, and both are OraSure companies.

In the maker’s own figures, first-void is the first 20 to 30 mL of the stream, typically the first 20 mL; collectors come in 4, 10, 20 and 40 mL, and the Urine Conservation Medium, at one part to three of sample, holds DNA for 7 days at room temperature, 14 days at 4 °C and up to 90 days frozen. Colli-Pee is CE-marked, its conservation-medium configurations CE-IVD marked, a US FDA Class 1 device, with research-use variants labelled as such.

Why it matters

The first catch carries the signal.

For urogenital targets, where in the stream you collect changes what you measure. The first-void fraction flushes cells and analytes shed from the urethra and lower genital tract, so it concentrates the signal that a random midstream sample dilutes. Standardising both which fraction and how much is collected is what makes urine a reproducible molecular matrix, the basis for the HPV, STI and biomarker evidence below.

First-void, by designA diverter captures the first-catch fraction every time, not a variable midstream sample.
Defined volumeThe tube fills to a set volume and stops, a standardised input for reproducible molecular results.
Stabilised optionA conservation medium can be prefilled to preserve DNA and analytes for ambient transport.
The evidence

What the record shows.

Each figure below belongs to the study that produced it. Colli-Pee is named where the paper’s abstract names it; the rest prove the first-void matrix the device standardises.

HPV screening, VALHUDESHigh-risk HPV testing on Colli-Pee first-void urine reached a relative sensitivity of 0.95 and a relative specificity of 1.03 for high-grade cervical precancer against clinician-taken cervical samples (Gynecologic Oncology, 2021).
STI testing at home, by post473 home Colli-Pee samples from 213 men, sent by regular post, agreed with clinic urine at kappa 0.75 for chlamydia, 0.87 for gonorrhoea and 0.85 for Mycoplasma genitalium (BMJ Open, 2019).
Volume against extraction25 women, Colli-Pee collectors of 4, 10 and 20 mL prefilled with conservation medium: the DNA extraction method changed the yield of human and HPV DNA more than the collected volume did (Molecules, 2021).
A second assay, the same result500 women, a different HPV assay: first-void urine matched cervical samples, sensitivity ratio 0.95 and specificity ratio 1.03 (Journal of Medical Virology, 2024).
Robust to over-collection27,042 first-void specimens, 1,611 of them overfilled: chlamydia and gonorrhoea positivity did not change (Microbiology Spectrum, 2025).
Antibodies in first-void urineVaccine-induced HPV antibodies, shed from cervicovaginal secretions, are measurable in first-void urine, a liquid-biopsy use beyond nucleic acids (Frontiers in Immunology, 2020).

Method validation runs per assay before a result is reported. The full reading list follows below.

How it works

Catch. Stabilise. Return.

01Catch

The patient starts urinating into the device; the diverter routes the first-void fraction into the collector.

02Stabilise

The tube fills to its defined volume and, where used, mixes the sample with a conservation medium.

03Seal & return

Cap and drop it in the tracked mailer, chain of custody from the first second.

On the platform

Assembled into a kit.

Colli-Pee is curated onto the platform and assembled into a regulated Humans Nexus collection kit: device, conservation medium where the assay requires it, tamper-evident return packaging and app-guided instructions, under its own UDI.

The deviceColli-Pee first-void collector at the volume the programme requires.
The stabilisationOptional DNA/analyte-conservation medium for ambient transport, plus tamper-evident return packaging.
The guidanceApp-guided instructions for a clean first-void collection at home.

Urine on the platform →

Who it’s for

For urogenital molecular work.

LaboratoriesA standardised first-void matrix for HPV and STI molecular testing
Screening programmesNon-invasive self-sampling to widen cervical-screening reach
Digital healthAt-home STI and urogenital testing behind your app
ResearchersReproducible first-void urine for biomarker and liquid-biopsy work

Good to know.

What does Colli-Pee collect?

A standardised, defined volume of first-void urine, the first 20 mL of the stream, the fraction richest in urogenital cells and analytes, captured by a diverter rather than a random midstream sample.

Why first-void rather than midstream urine?

For urogenital targets such as HPV and STIs, the first-void fraction concentrates the cells and analytes shed from the lower genital tract that a midstream sample dilutes, which is why it is the preferred molecular matrix.

Which volumes does Colli-Pee come in?

4, 10, 20 and 40 mL collectors, per the maker. The first 20 mL is the fraction that matters; the assay sets the volume, and in Colli-Pee tubes of 4, 10 and 20 mL the DNA extraction method changed the yield more than the volume did.

How long is the sample stable?

With the conservation medium, DNA for 7 days at room temperature, 14 days at 4 °C and up to 90 days frozen, per the maker; neat urine follows the laboratory’s rule for the assay.

Is first-void urine validated for HPV screening?

In the VALHUDES study, high-risk HPV testing on Colli-Pee first-void urine reached a relative sensitivity of 0.95 and a relative specificity of 1.03 for high-grade cervical precancer against clinician-taken cervical samples, with a validated assay and cut-off.

Can it be used at home for STI testing?

Yes. In 213 men sending 473 Colli-Pee samples by regular post, home first-void urine agreed with clinic urine at kappa 0.75 for chlamydia, 0.87 for gonorrhoea and 0.85 for Mycoplasma genitalium.

What is its regulatory status?

Colli-Pee is CE-marked, its conservation-medium configurations are CE-IVD marked and it is a US FDA Class 1 device, per the manufacturer; research-use variants are labelled as such. Device-level regulatory status is held by DNA Genotek; Humans Nexus assembles the regulated kit around it and validates the method per assay before patient-facing reporting.

Who is the manufacturer?

DNA Genotek is the legal manufacturer; the device was invented by Novosanis, and both are OraSure companies. Humans Nexus curates and supplies it on the platform and assembles the kit around it.

OpenSampling Library by Humans Nexus

Library Colli-Pee

  1. Evaluating DNA methylation markers and extended HPV genotyping in first-void urine for detecting high-grade cervical lesions in HPV-positive women: a cross-sectional study

    BMC medicine · 2026 · Open access

    DNA methylation markers in first-void urine effectively detect high-grade cervical lesions in HPV-positive women, with results similar to clinician-collected samples in those over 30. This enables reliable cervical cancer screening using self-collected urine,

    Read in the Library

  2. Agreement and Diagnostic Performance of Urinary HPV Testing Versus Clinician-Collected Cervico-Vaginal Sampling: A Prospective Cross-Sectional Study in a Romanian Cohort

    Medical sciences · 2026 · Paywalled

    Urinary HPV testing using first-void urine collected with the Colli-Pee device showed substantial agreement with clinician-collected cervico-vaginal sampling and near-equivalent negative predictive value, supporting its use as a clinically credible non-invasive entry point for

    Read in the Library

  3. The importance of first-void urine for assessing HPV-specific antibodies: A comparison with midstream urine

    Human vaccines & immunotherapeutics · 2026 · Open access

    First-void urine samples showed significantly higher detection rates of HPV-specific IgG antibodies compared to midstream urine, confirming the necessity of capturing the initial stream. The study found no significant difference between 10 mL and 20 mL collection

    Read in the Library

  4. Accuracy of HPV Testing Using Self-collected Urine Compared With Physician-collected Cervical Specimen for HSIL or Worse

    Journal of lower genital tract disease · 2026 · Paywalled

    This meta-analysis found that self-collected urine samples for HPV testing had lower sensitivity for detecting high-grade lesions compared to physician-collected cervical specimens. The use of a first-void collection device such as Colli-Pee was

    Read in the Library

  5. Comparison of three different hpv self-sampling tools - a subanalysis of the prospective, randomized hannover self-collection study

    Archives of gynecology and obstetrics · 2026 · Open access

    This randomised sub-study found return rates of 10.4% for Colli-Pee, 10.1% for FLOQSwabs and 7.4% for Evalyn-Brush. All devices yielded sufficient DNA with low invalid rates, but the

    Read in the Library

  6. Evaluation of the Quality and Suitability of Self-Collected Vaginal and Urine Samples for Human Papillomavirus Testing: A Prospective Matched Study

    BJOG · 2026 · Open access

    For decentralised testing, a study found dry vaginal self-samples using Copan FLOQSwabs stored up to two weeks at room temperature maintain DNA quality. However, first-void urine collected with the Colli-Pee device may be less sensitive for HPV detection,

    Read in the Library

All 59 in the OpenSampling Library

These citations describe the published evidence for the collection formats and devices, not claims about specific Humans Nexus assays, which are validated per analyte and per laboratory.

Put first-void urine on your platform.

Talk to us about Colli-Pee for your HPV, STI or biomarker programme.

Talk to salesUrine on the platform →